Lubrizol

Lubrizol Licenses Award-Winning Apisolex Excipient to Welton Pharma to Develop a Novel Cancer Therapeutic

CLEVELAND, US - 21 June 2023 - The Lubrizol Corporation announces the licensing of its novel excipient polymer technology, Apisolex excipient, to Welton Pharma (Welton). The license allows Welton to use the Apisolex excipient worldwide to develop and commercialise a novel formulation of SN-38 to treat colorectal and associated gastro-intestinal cancers.
The Lubrizol Corporation 29400 Lakeland Boulevard Wickliffe, Ohio 44092 USA

+1 440 943 4200